{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-021463","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.224485+00:00","generated_at":"2026-06-17T23:15:07.255166+00:00","sec_items":["5.03","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Allarity stockholders approve 25x increase in authorized shares and reverse stock split authorization","bullets":["Approved increase in authorized shares from 30,500,000 to 750,500,000 and common stock from 30,000,000 to 750,000,000.","Approved reverse stock split at ratio between 1-for-20 and 1-for-35; Board will determine final ratio.","Vote results: Share increase: 34,265,983 for, 410,898 against; Reverse split: 34,308,947 for, 361,101 against.","Certificate of Amendment filed with Delaware Secretary of State on March 20, 2023.","Reverse stock split authorization may allow company to meet Nasdaq minimum bid price requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-021463","json":"https://secwatch.observer/filing/0001213900-23-021463.json","markdown":"https://secwatch.observer/filing/0001213900-23-021463.md","text":"https://secwatch.observer/filing/0001213900-23-021463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023021463/0001213900-23-021463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023021463/ea175532-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:15:07.255166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf08108e7cedb91713a5a69f2db00813b06a8998","claim":"Allarity Therapeutics, Inc.: Increased authorized shares from 30,500,000 to 750,500,000 and common stock from 30,000,000 to 750,000,000 (effective 2023-03-20).","evidence_excerpt":"an amendment to Allarity Therapeutics, Inc.’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to increase the number of authorized shares from 30,500,000 to 750,500,000, and to increase the number of shares of common stock (the “Common Stock”) from 30,000,000 to 750,000,000 (the “Share Increase”) was approved","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023021463/0001213900-23-021463-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-03-20"}],"fact_type":"governance_change"},{"claim_id":"322f255d3ffb2d971501fc5b93b20a9c684441e2","claim":"Allarity Therapeutics, Inc. shareholders approved Approve amendment to Certificate of Incorporation to increase authorized shares from 30,500,000 to 750,500,000 and Common Stock from 30,000,000 to 750,000,000 at the 2023-03-20 meeting.","evidence_excerpt":"Proposal 1: To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares from 30,500,000 to 750,500,000, and to increase the number of our Common Stock from 30,000,000 to 750,000,000, in substantially the form attached to the Proxy Statement as Appendix A (the “Share Increase Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 34,265,983 410,898 11,500 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023021463/0001213900-23-021463-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-03-20"}],"fact_type":"shareholder_vote"},{"claim_id":"97bfaa1415b386a3748d23c457c5da580b2989c5","claim":"Allarity Therapeutics, Inc. shareholders approved Approve amendment to Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-20 and 1-for-35, at the discretion of the Board at the 2023-03-20 meeting.","evidence_excerpt":"Proposal 2: To approve an amendment to our Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding Common Stock, par value $0.0001 per share, at a ratio between 1-for-20 and 1-for-35 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement. Votes For Votes Against Abstentions Broker Non-Votes 34,308,947 361,101 18,333 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023021463/0001213900-23-021463-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-03-20"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}